Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERAP2 | Q6P179 | 4/20 | 0.56 |
| ▸ | KISS1R | Q969F8 | 15/20 | 0.55 |
| ▸ | CTSC | P53634 | 1/20 | 0.51 |
| ▸ | IL1RN | P18510 | 3/20 | 0.50 |
| ▸ | ERAP1 | Q9NZ08 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29727424 | 0.94 | ERAP2 (0.56) | ERAP2KISS1R | |
| SCHEMBL30721587 | 0.93 | ERAP2 (0.57) | ERAP2KISS1RIL1RNERAP1 | |
| SCHEMBL30108349 | 0.93 | KISS1R (0.55) | ERAP2KISS1RIL1RNERAP1 | |
| SCHEMBL30617785 | 0.92 | ERAP2 (0.64) | ERAP2KISS1RIL1RNERAP1 | |
| SCHEMBL29436295 | 0.91 | KISS1R (0.56) | ERAP2KISS1R | |
| SCHEMBL31047373 | 0.91 | KISS1R (0.57) | KISS1R | |
| SCHEMBL30301902 | 0.90 | KISS1R (0.60) | KISS1R | |
| SCHEMBL29390396 | 0.90 | MAGI3 (0.55) | ERAP2KISS1R | |
| SCHEMBL30465916 | 0.88 | ERAP2 (0.64) | ERAP2IL1RNERAP1 | |
| SCHEMBL32667969 | 0.88 | ERAP2 (0.60) | ERAP2KISS1RIL1RNERAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240277816-A1 | POLYPEPTIDE CONJUGATE AND APPLICATION THEREOF IN PREPARATION OF DRUG FOR TREATING DISEASES RELATED TO GLUCOSE METABOLISM | PEGBIO CO., LTD. (CN) | 2024-08-22 | — | — | US | claimed |
| WO-2023001186-A1 | POLYPEPTIDE CONJUGATE AND APPLICATION THEREOF IN PREPARATION OF DRUG FOR TREATING DISEASES RELATED TO GLUCOSE METABOLISM | 派格生物医药(苏州)股份有限公司 | 2023-01-26 | — | — | WO | claimed |
| US-12516095-B2 | Peptide hormone analogues | IP2IPO INNOVATIONS LIMITED (GB) | 2026-01-06 | — | — | US | disclosed |
| US-12508229-B2 | Method for preparing stable peptide formulations | AMPHASTAR PHARMACEUTICALS, INC. (US) | 2025-12-30 | — | — | US | disclosed |
| US-20250368710-A1 | NOVEL COMPOUNDS | IP2IPO INNOVATIONS LTD (GB) | 2025-12-04 | — | — | US | disclosed |
| US-12370241-B2 | Nasal powder formulation for treatment of hypoglycemia | AMPHASTAR PHARMACEUTICALS, INC. (US) | 2025-07-29 | — | — | US | disclosed |
| US-20250114463-A1 | LIVER-TARGETED DRUG AND USE THEREOF | HANMI PHARM. CO., LTD. (KR) | 2025-04-10 | — | — | US | disclosed |
| US-12226456-B2 | Nasal powder formulation for treatment of hypoglycemia | AMPHASTAR PHARMACEUTICALS, INC. (US) | 2025-02-18 | — | — | US | disclosed |
| US-20240336669-A1 | NOVEL COMPOUNDS | IP2IPO INNOVATIONS LIMITED (GB) | 2024-10-10 | — | — | US | disclosed |
| US-20240277816-A1 | POLYPEPTIDE CONJUGATE AND APPLICATION THEREOF IN PREPARATION OF DRUG FOR TREATING DISEASES RELATED TO GLUCOSE METABOLISM | PEGBIO CO., LTD. (CN) | 2024-08-22 | — | — | US | disclosed |
| US-12018060-B2 | Glucagon derivatives | HANMI PHARM CO., LTD. (KR) | 2024-06-25 | — | — | US | disclosed |
| WO-2022123271-A1 | NOVEL COMPOUNDS | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2022-06-16 | — | — | WO | disclosed |
| US-11332508-B2 | Triple glucagon/GLP-1/GIP receptor agonist | HANMI PHARM. CO., LTD. (KR) | 2022-05-17 | — | — | US | disclosed |
| US-20220127325-A1 | GLUCAGON DERIVATIVE AND A COMPOSITION COMPRISING A LONG ACTING CONJUGATE OF THE SAME | HANMI PHARM. CO., LTD. (KR) | 2022-04-28 | — | — | US | disclosed |
| US-20220088148-A1 | A PHARMACEUTICAL COMPOSITION COMPRISING INSULIN AND TRIGONAL GLUCAGON/GLP-1/GIP RECEPTOR AGONIST | HANMI PHARM, CO., LTD. (KR) | 2022-03-24 | — | — | US | disclosed |
| US-11274136-B2 | Acylated glucagon analogue | ZEALAND PHARMA A/S (DK) | 2022-03-15 | — | — | US | disclosed |
| US-20220064248-A1 | PHARMACEUTICAL COMPOSITION INCLUDING INSULIN AND GLUCAGON | HANMl PHARM. CO., LTD (KR) | 2022-03-03 | — | — | US | disclosed |
| US-11261227-B2 | Glucagon derivative and a composition comprising a long acting conjugate of the same | HANMI PHARM. CO., LTD. (KR) | 2022-03-01 | — | — | US | disclosed |
| US-11254724-B2 | Glucagon derivatives | HANMI PHARM. CO., LTD. (KR) | 2022-02-22 | — | — | US | disclosed |
| US-20220025012-A1 | GLUCAGON DERIVATIVES | HANMI PHARM IND CO LTD (KR) | 2022-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240336669-A1 | NOVEL COMPOUNDS | GLP1R, GIPR, GPR119 | ERAP2 311/4885KISS1R 145/4885CTSC 82/4885 |
| US-20240277816-A1 | POLYPEPTIDE CONJUGATE AND APPLICATION THEREOF IN PREPARATION OF DRUG FOR TREATING DISEASES RELATED TO GLUCOSE METABOLISM | IAPP, GIPR, GCG | ERAP2 1127/4885KISS1R 526/4885CTSC 646/4885 |
| US-20250114463-A1 | LIVER-TARGETED DRUG AND USE THEREOF | PYGL, GYS2, FABP1 | ERAP2 167/4885KISS1R 3434/4885CTSC 190/4885 |
| US-12508229-B2 | Method for preparing stable peptide formulations | IAPP, GLP1R, GCG | ERAP2 1938/4885KISS1R 831/4885CTSC 66/4885 |
| US-20250368710-A1 | NOVEL COMPOUNDS | GLP1R, GPR119, GIPR | ERAP2 605/4885KISS1R 238/4885CTSC 107/4885 |
| US-11274136-B2 | Acylated glucagon analogue | GLP1R, GCGR, GIPR | ERAP2 761/4885KISS1R 138/4885CTSC 135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.